Key Points
- CEO Dinesh Ph Patel sold 54,641 shares of Protagonist Therapeutics on March 25 at an average price of $101, totaling about $5.52 million, reducing his ownership by 9.43% to 524,938 shares (valued ≈ $53.0 million).
- The company posted a Q4 miss with EPS of ($0.69) vs. ($0.53) expected and revenue of $7.44M vs. $14.92M expected, while the stock trades near its 52-week high (opened ~$104) and the firm has a market cap of ~$6.66 billion.
- Analysts are broadly bullish—13 buys, 1 hold and 1 sell—with an average target of $107.31 and several recent target upgrades (examples: HC Wainwright $117, Jefferies $121, Barclays $119, JPMorgan $106).
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,641 shares of Protagonist Therapeutics stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $101.00, for a total value of $5,518,741.00. Following the transaction, the chief executive officer directly owned 524,938 shares of the company's stock, valued at approximately $53,018,738. This represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Protagonist Therapeutics Stock Performance
Protagonist Therapeutics stock opened at $104.31 on Thursday. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of -50.88 and a beta of 2.23. Protagonist Therapeutics, Inc. has a fifty-two week low of $39.60 and a fifty-two week high of $105.69. The stock's fifty day moving average is $88.30 and its two-hundred day moving average is $81.90.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The firm had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%. As a group, sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms have weighed in on PTGX. HC Wainwright raised their target price on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a report on Friday, January 30th. JPMorgan Chase & Co. upped their price target on shares of Protagonist Therapeutics from $95.00 to $106.00 and gave the company an "overweight" rating in a report on Thursday, March 19th. Barclays increased their price target on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an "overweight" rating in a research report on Thursday, March 19th. Citizens Jmp lifted their price objective on Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 26th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $107.31.
Read Our Latest Research Report on Protagonist Therapeutics
Institutional Trading of Protagonist Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC raised its stake in Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company's stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $27,000. Salomon & Ludwin LLC acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company's stock worth $36,000 after buying an additional 314 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $62,000. Hedge funds and other institutional investors own 98.63% of the company's stock.
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
